Clinical trial
Twin SUBLIVAC® Grasses Clinical Efficacy Study
NCT00422149 · HAL Allergy, Industry · Completed
Key facts
| NCT number | NCT00422149 |
|---|---|
| Title | Twin SUBLIVAC® Grasses Clinical Efficacy Study |
| Official title | Twin SUBLIVAC® Grasses Clinical Efficacy Study |
| Lead sponsor | HAL Allergy, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Seasonal, Conjunctivitis |
| Intervention type | Drug |
| Interventions | SUBLIVAC® Grasses/Placebo treatment, SUBLIVAC® Grasses treatment, Placebo treatment |
| Enrollment | 350 |
| Start date | Sep 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jan 15, 2007 |
| Last update posted | Feb 7, 2012 |
| Countries | Belgium, Germany, Netherlands, Poland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: